Search Results
483 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks
Additional information about the conference is available at http://www.alz.org/aaic/. projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds
These scaffold proteins (AKAP150) are a key part of post-synaptic complexes critical for synaptic transmission projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Reports That New Data Confirms Calcium Target Over-Expression May Be Involved in Causing AD
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email:info@anavex.com Shareholder & Media Relations Toll-free: 1-866-
- Anavex Provides Business Update Including Clinical Trial Plans for ANAVEX PLUS in AD
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Strengthens Scientific Advisory Board with Clinical Trial Expert
Relkin is a Weill Cornell Medical College neurologist and an internationally recognized expert on Alzheimer He is currently an Associate Professor of Neurology at the Weill Cornell Medical College and Founding projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
financial acumen will be invaluable to Anavex as we work to develop novel drugs for the treatment of unmet medical and has 10 years of basic science laboratory experience working on human genetics projects at Harvard Medical projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Encouraged by Scientific Data; Sigma-1 Receptor Agonist is Potentially Disease-Modifying
Angela Cenci and colleagues from the Departments of Experimental Medical Science and Clinical Sciences projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Successfully Closes $10M Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Announces $10M Private Placement of Convertible Debentures
projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS
Most people with ALS die from respiratory failure within three to five years from the onset of symptoms projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
